Sanofi, an innovative biopharmaceutical company, has appointed Michaela Scheiffert as General Manager Pharma for Central and Southern Europe (MCO) and Pharma Head and Country Lead for Poland. The combination of these two functions underscores the country's growing importance within Sanofi's structures and its influence in shaping healthcare policy in Europe. With the dynamic development of the clinical research ecosystem, digitization and artificial intelligence (AI) applications, Poland is uniquely positioned to support Sanofi's strategic goals in the region. In her new role, Michaela Scheiffert will be responsible for executing the company's global strategy, with a strong focus on immunology and the development of breakthrough therapies.
Sanofi with new Country Lead in Poland
Published Jan. 27, 2025 10:18
Sanofi's multinational organization (MCO) structure, which includes Poland, the Czech Republic, Hungary, Romania, Greece, Ukraine, Israel and 15 partner markets in Europe, plays a key role in the pharmaceutical company's global operations. Sanofi serves millions of patients each year, contributing significantly to its extensive research and development (R&D) portfolio, which now includes 78 clinical projects worldwide. A significant portion of Sanofi's clinical research is conducted specifically in the CSE region, underscoring its strategic importance in driving innovation. The decision to entrust the leader of CSE MCO with the position of CEO of Sanofi Poland at the same time further underscores the country's key role in the region's structures.
Michaela Scheiffert has extensive experience in managing business operations in various therapeutic areas and leading strategic initiatives to grow the healthcare and pharma sectors. During her career at Sanofi, she held key roles including South Europe MCO Lead and Country Lead, successfully implementing strategies that strengthened market presence and ensured sustainable business growth.
- Poland, thanks to its strategic location, booming economy and status as the fifth most populous country in the European Union, plays an important role in shaping health policy in Central and Southern Europe. In recent years, the country has demonstrated its growing potential for innovation, with domestic public and private sector R&D expenditures increasing by nearly 19 percent to PLN 53.1 billion in 2023. This progress dovetails perfectly with Sanofi's recent €2 billion investment in R&D in Europe, which has contributed to the development of immunology and the use of artificial intelligence to create breakthrough therapies to meet the needs of patients with diseases of this nature, emphasizes Michaela Scheiffert, General Manager Pharma for Central and Southern Europe (MCO) and Pharma Head and Country Lead at Sanofi Poland. - Poland's role is particularly important during the ongoing Polish Presidency of the EU Council. This is an extraordinary opportunity to shape the future of the European health care system, especially in the area of prevention, which occupies a central place in Sanofi's activities. I feel honored to be part of this groundbreaking effort, and I am ready to work with partners from across the region to make a real difference together.
The strategic focus on Poland as a center of innovation and leadership reflects the ongoing transformation within the company's structures. The change in Sanofi Poland's leadership team is aimed at aligning with the company's global goals and further strengthening its position as a key player in the region.
Source: Press Mat.
